首页 > 市场调查报告书 > 製药

呼吸器

市场调查报告书

商品编码

1708767

全球鲍氏不动桿菌肺炎治疗市场依药物类别、给药途径及地区划分

Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, By Route of Administration, By Geography

出版日期: 2025年03月04日 | 出版商:

Coherent Market Insights | 英文 132 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计 2025 年全球鲍氏不动桿菌肺炎治疗市值为 7.251 亿美元，到 2032 年将达到 10.76 亿美元。预计 2025 年至 2032 年的年复合成长率(CAGR)为 5.8%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	7.251亿美元
效能数据	2020-2024	预测期	2025-2032
预测期间：2025年至2032年的复合年增长率	5.80%	2032年价值预测	10.76亿美元

数字。 2025年全球鲍氏不动桿菌肺炎药物各地区全球市场占有率（%）

鲍氏不动桿菌肺炎是一种由鲍氏不动桿菌属细菌引起的一种严重肺炎。这些细菌通常存在于土壤和水中。近年来，由多重抗药性不动鲍氏不动桿菌菌株引起的医院内肺炎病例急剧增加。它通常影响免疫力缺乏的患者和加护病房接受机械通气的患者。抗生素抗药性是鲍氏不动桿菌肺炎治疗的一大挑战。当务之急是针对这种病原体采取新的治疗方法。

市场动态

全球鲍氏不动桿菌肺炎治疗市场受到抗药性菌株的传播以及医院获得性肺炎或人工呼吸器相关性肺炎发病率的增加所驱动。根据美国疾病管制与预防中心的数据，鲍氏不动桿菌感染疾病每年占美国美国内获得性肺炎病例的 8% 至 10%。此外，有限的抗生素管道和缺乏针对鲍氏不动桿菌肺炎的核准治疗方法也为该市场创造了机会。然而，高昂的开发成本和新药认证相关的监管障碍阻碍了市场的成长。市场受到多种因素的影响，例如多重抗药性菌株的增加、诊断技术的进步以及对有效治疗方案的需求。製药公司、研究机构和医疗保健提供者之间的合作在推进治疗方案方面发挥关键作用。不断演变的感染疾病情势和 COVID-19 大流行的影响凸显了透过创新治疗性介入和公共卫生措施持续努力应对鲍氏不动桿菌肺炎的重要性。

研究的主要特点

本报告对全球鲍氏不动桿菌肺炎治疗市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和復合年增长率。

它还强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的主要考察。

根据公司亮点、产品系列、关键亮点、绩效和策略等参数，列出了全球鲍氏不动桿菌肺炎治疗市场的主要企业。

主要企业包括辉瑞、默克、葛兰素史克 (GSK)、阿斯特捷利康、诺华、强生、赛诺菲、拜耳、巴塞利亚製药等。

本报告的见解将使负责人和企业经营团队能够就未来的产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。

全球鲍氏不动桿菌肺炎治疗药物市场报告针对该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

相关人员可以透过全球鲍氏不动桿菌肺炎治疗药物市场分析中使用的各种策略矩阵来促进决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 725.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	5.80%	2032 Value Projection:	USD 1,076. Mn

Acinetobacter pneumonia is a severe type of pneumonia caused by the Acinetobacter species of bacteria. These bacteria are commonly found in soil and water. In recent times, there has been a steep rise in the number of cases of hospital-acquired pneumonia caused by multidrug-resistant Acinetobacter strains. Typically, it affects immunocompromised patients or those on mechanical ventilation in intensive care units. Antibiotic resistance has emerged as a major challenge in treating Acinetobacter pneumonia. Novel therapeutic approaches targeting this pathogen are the need of the hour.

Market Dynamics:

The global Acinetobacter pneumonia therapeutics market is driven by the growing prevalence of drug-resistant strains and increasing incidence of hospital-acquired or ventilator-associated pneumonia. According to the Centers for Disease Control and Prevention, Acinetobacter infections account for 8-10% of all hospital-acquired pneumonia cases in the U.S. every year. Moreover, the restricted antibacterial pipeline and lack of approved therapies specific to Acinetobacter pneumonia act as opportunities in the market. However, high development costs and regulatory hurdles associated with new drug approvals hamper the market growth. The market is influenced by factors such as increasing incidence of multidrug-resistant strains, advancements in diagnostic technologies, and the need for effective treatment options. Collaborations between pharmaceutical companies, research institutions, and healthcare providers play a crucial role in advancing therapeutic solutions. The evolving landscape of infectious diseases and the impact of the COVID-19 pandemic underscore the importance of sustained efforts to address Acinetobacter pneumonia through innovative therapeutic interventions and public health measures.

Key Features of the Study:

This report provides an in-depth analysis of the global acinetobacter pneumonia therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global acinetobacter pneumonia therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG, Johnson & Johnson, Sanofi S.A., Bayer AG, and Basilea Pharmaceutica

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global acinetobacter pneumonia therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acinetobacter pneumonia therapeutics market.

Detailed Segmentation:

Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
- Cephalosporins
- Carbapenems
- Aminoglycosides
- Polymyxins
Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
- Oral
- Intravenous
- Others
Global Acinetobacter Pneumonia Therapeutics Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc (GSK)
- AstraZeneca plc
- Novartis AG
- Johnson & Johnson
- Sanofi S.A.
- Bayer AG
- Basilea Pharmaceutica

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class
- Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration
- Global Acinetobacter Pneumonia Therapeutics Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Rising prevalence of Acinetobacter pneumonia infections
- Increasing research & development activities
- Growing healthcare expenditure
Impact Analysis
Key Highlights
Regulatory Scenario
Service offering Portfolio
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Pipeline Analysis

4. Global Acinetobacter Pneumonia Therapeutics Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Acinetobacter Pneumonia Therapeutics Market, By Drug Class, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cephalosporins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Carbapenems
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Aminoglycosides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Polymyxins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Acinetobacter Pneumonia Therapeutics Market, By Route of Administration, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Acinetobacter Pneumonia Therapeutics Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
GlaxoSmithKline plc (GSK)
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca plc
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Basilea Pharmaceutica
- Company Highlights
- Drug Class Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views

9. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

全球鲍氏不动桿菌肺炎治疗市场依药物类别、给药途径及地区划分